Case Report of Pembrolizumab Response in Metastatic Anal Cancer with HPV DNA Biomarker

figshare admin karger published a case report PDF in 2026 detailing a complete response to pembrolizumab in a heavily pretreated patient with metastatic anal squamous cell carcinoma. The 1.2 MB document describes the use of circulating tumor tissue modified viral HPV DNA as a biomarker for early detection of treatment response. The dataset is a single case report under a CC-BY-4.0 license.

Use Cases

• Reviewing a clinical case of successful immunotherapy based on the detailed patient history described.
• Studying the application of circulating tumor DNA as a biomarker based on the monitoring data mentioned in the report.
• Analyzing treatment response patterns in rare cancers based on the documented outcome for metastatic anal squamous cell carcinoma.

Strengths

• Document is a detailed, peer-reviewed case report focusing on a rare cancer subtype.
• Includes specific biomarker data (circulating tumor tissue modified viral HPV DNA) for treatment monitoring.
• Released under a permissive CC-BY-4.0 license for reuse.

Limitations

• Dataset is a single case report (n=1), limiting statistical power and generalizability.
• Row count and column-level documentation are absent; data structure must be inferred from the PDF.
• Description metadata is limited; actual data quality requires manual inspection after download.

Provenance

Source

figshare admin karger

Collection Method

Clinical case documentation and analysis.

Freshness

Last updated 2026-04-21 05:55:29; freshness should be verified.